Rubicon Research Expands Indian Operations with Arinna Acquisition
Rubicon Research sharpens India play in CNS push with Arinna acquisition
Business Standard
Image: Business Standard
Rubicon Research, primarily generating over 95% of its revenue from the United States, is enhancing its presence in India through the acquisition of Arinna. This move is part of a global strategy focused on central nervous system (CNS) therapies, according to CEO Parag Sancheti.
- 01Rubicon Research's revenue is predominantly from the US market.
- 02The acquisition of Arinna aims to strengthen Rubicon's market presence in India.
- 03The focus of the acquisition is on CNS therapies.
- 04CEO Parag Sancheti emphasizes expanding market reach rather than a geographical shift.
- 05This move aligns with Rubicon's broader global strategy.
Advertisement
In-Article Ad
Rubicon Research, a company that currently derives over 95% of its revenue from the United States, is enhancing its operations in India through the acquisition of Arinna. This strategic move aims to bolster Rubicon's presence in the central nervous system (CNS) therapies market. CEO Parag Sancheti highlighted that the acquisition is intended to expand the company's go-to-market footprint rather than signify a geographical pivot. This initiative is part of Rubicon's broader global strategy to strengthen its position in the CNS sector, indicating a commitment to growth in emerging markets like India.
Advertisement
In-Article Ad
This acquisition may lead to increased investment in the Indian market, potentially creating jobs and enhancing access to CNS therapies for local patients.
Advertisement
In-Article Ad
Reader Poll
Do you think pharmaceutical companies should expand their operations in emerging markets like India?
Connecting to poll...
More about Rubicon Research
Read the original article
Visit the source for the complete story.